Balyasny Asset Management
MRKR icon

Balyasny Asset Management’s Marker Therapeutics MRKR Stock Holding History

Balyasny Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,319
Closed -$580K – 1428
2019
Q2 		$580K Buy
+7,319
New +$435K ﹤0.01% 1196

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Balyasny Asset Management's MRKR Position: Q3 2019 in Review

Balyasny Asset Management sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 7,319 shares — an estimated $580K sold.

Balyasny Asset Management first reported a position in MRKR in Q2 2019 and held it in 1 quarter. The position peaked at $580K in Q2 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Balyasny Asset Management reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Balyasny Asset Management sold 7,319 Marker Therapeutics shares in Q3 2019, an estimated $580K.
  • Balyasny Asset Management first reported a position in Marker Therapeutics in Q2 2019 and held it in 1 quarter.
  • Balyasny Asset Management's Marker Therapeutics position peaked at $580K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.